Clinical Spotlights in the Treatment of Relapsed/Refractory Myeloma: Novel Publications with anti-CD38-based Combinations
Evangelos Terpos, MD, PhD
Department of Clinical Therapeutics, Plasma Cell Dyscrasias Unit, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
During the last 3 months, the results of two important phase-3 studies, using anti-CD38 monoclonal antibodies for the treatment of relapsed/refractory myeloma (RRMM), were published.
The first is the IKEMA study that was published in the June issue of Lancet. This is a phase 3, open-label study compared the efficacy of isatuximab plus carfilzomib-dexamethasone (IsaKd) versus carfilzomib-dexamethasone (Kd) in patients with RRMM… read more
The second is the APOLLO study that was published in the June issue of Lancet Oncology. This was a phase 3 study which compared the combination of daratumumab plus pomalidomide and dexamethasone (DaraPomDex) versus pomalidomide and dexamethasone (PomDex) alone in patients with previously treated multiple myeloma….read more
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
